论文部分内容阅读
总结了2019年度美国重症肌无力（MG）基金会科学会议的主要内容，得出以下结论：肌肉特异性受体酪氨酸激酶抗体阳性MG（MuSK-MG）仍是如今MG研究中的热门领域，MuSK-MG的临床研究、临床药物研究以及基础实验研究均是重点研究内容。胸腺切除术对乙酰胆碱受体抗体阳性MG（AChR-MG）安全有效，对其他类型MG的安全性和有效性有待进一步研究，伴或不伴胸腺瘤的AChR-MG患者均能从胸腺切除术中获益。对MG目前仍缺少特效药物，单克隆抗体药物是MG研究中的有效药物，随着不同作用机制的单克隆抗体药物的出现，MG将会有更好的治疗效果。MG基础实验研究越来越关注B细胞的起源和凋亡异常在MG致病机制中的作用。希望能为国内同仁提供参考。“,”The main content of the 2019 Myasthenia Gravis Foundation of America Scientific Session is summarized, and the main conclusions are presented as follows: Muscle-specific receptor tyrosine kinases antibody positive myasthenia gravis (MuSK-MG) is still the research hot spot in MG research fields, including the clinical researches, the clinical pharmaceutical researches and the fundamental experiment researches. Thymectomy shows safety and effectiveness for acetycholine receptor antibody positive MG (AChR-MG). However, thymectomy needs further discussion about the safety and effectiveness for other types of MG. AChR-MG patients with or without thymoma can benefit from thymectomy. Now there are still no special effective drugs to cure MG, and monoclonal antibody drugs are the hopes for MG patients. With the emergence of different kinds of monoclonal antibodies, MG will be more likely to be conquered. More attention has been paid to the role of B cells′ origin and apoptosis abnormality in the pathogenesis of MG in MG researches.